An open label, randomized, parallel, phase II trial to evaluate the efficacy and safety of cremophor-free, polymeric micelle formulation of paclitaxel compared to paclitaxel in subjects with ovarian cancer.

被引：0
|
作者：
Kim, Yong-Man
Lee, Shin-Wha
Cho, Chi Heum
Hur, Soo-Young
Kim, Byoung-Gie
Kim, Jae Hoon
Kim, Seung Cheol
Kim, Seok-Mo
Kim, Young-Tae
Ryu, Hee Sug
Kang, Soon-Beom
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[2] Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Taegu, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Seoul, South Korea
[6] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Obstet & Gynecol, Seoul, South Korea
[7] Chonnam Natl Univ, Sch Med, Dept Obstet & Gynecol, Kwangju, South Korea
[8] Yonsei Univ, Severance Hosp, Dept Obstet & Gynecol, Seoul 120749, South Korea
[9] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon 441749, South Korea
[10] Konkuk Univ, Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5568
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cremophor EL-free formulation of paclitaxel: A randomized, multicenter, safety, and efficacy study of nanosomal paclitaxel lipid suspension (NPLS) versus paclitaxel in women with metastatic breast cancer (MBC)
    Ahmad, Ateeq
    Sheikh, Saifuddin
    Mehta, Ajay O.
    Nagarkar, Rajnish Vasant
    Srinivasan, Krishnan
    Majumdar, Anup
    Mukherjee, Kalyan Kusum
    Singh, Jitendra K.
    Shrivastav, S. P.
    Satheesh, C. T.
    Maksud, Tanveer
    Pawar, Suraj
    Sonawane, Satish Ramkrishna
    Kamat, Satish V.
    Sharma, Manish
    Rane, R. C.
    Ahmad, Imran
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] AN OPEN-LABEL RANDOMIZED ACTIVE-CONTROLLED PHASE II CLINICAL STUDY TO ASSESS EFFICACY AND SAFETY OF AFURESERTIB PLUS PACLITAXEL VERSUS PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
    Yue, Y.
    Shen, H.
    Lu, C.
    Hughes, B. N.
    Coleman, R. L.
    Monk, B. J.
    Herzog, T. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A78 - A78
  • [23] An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer
    Y Chao
    C P Li
    T Y Chao
    W C Su
    R K Hsieh
    M F Wu
    K H Yeh
    W Y Kao
    L T Chen
    A L Cheng
    British Journal of Cancer, 2006, 95 : 159 - 163
  • [24] An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer
    Chao, Y.
    Li, C.
    Chao, T. Y.
    Su, W. C.
    Hsieh, R. K.
    Wu, M. F.
    Yeh, K. H.
    Kao, W. Y.
    Chen, L. T.
    Cheng, A. L.
    BRITISH JOURNAL OF CANCER, 2006, 95 (02) : 159 - 163
  • [25] Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial
    Li, Rong
    Zhang, Hongping
    Li, Qingshui
    Yuan, Guangwen
    Zhou, Yanjie
    Yin, Rutie
    Wang, He
    Wang, Chunyan
    Huang, Yi
    Wang, Wei
    Yan, Xiaojian
    Wu, Lingying
    Zhou, Qi
    JOURNAL OF THE NATIONAL CANCER CENTER, 2024, 4 (02): : 135 - 141
  • [26] Phase II randomized trial of cisplatin/paclitaxel plus lonidamine versus cisplatin/ifosfamide plus lonidamine in the treatment of ovarian cancer.
    Lorusso, V
    Calabrese, R
    Latorre, A
    Guida, M
    Misino, A
    Spada, M
    Paradiso, A
    De Lena, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 879S - 879S
  • [27] Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial
    Li, Li
    Zhuang, Qingqing
    Cao, Zeyi
    Yin, Rutie
    Zhu, Yaping
    Zhu, Lirong
    Xie, Xing
    Zhang, Youzhong
    Li, Li
    Wu, Qiang
    Zheng, Jianhua
    Zhou, Qi
    Li, Xiaoping
    Wu, Lingying
    Feng, Youji
    Wang, Changyu
    ONCOLOGY LETTERS, 2018, 15 (03) : 3646 - 3652
  • [28] Randomized phase II trial comparing IG-001 versus paclitaxel against first-line advanced ovarian cancer.
    Trieu, Vuong N.
    Choi, Monica
    Hwang, Larn
    D'Cruz, Osmond
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.
    Li, Li
    Zhuang, Qingqing
    Cao, Zeyi
    Yin, Ru Tie
    Zhu, Yaping
    Zhu, Lirong
    Xie, Xing
    Zhang, Youzhong
    Li, Li
    Wu, Qiang
    Zheng, Jianhua
    Zhou, Qi
    Li, Xiaoping
    Wu, Lingying
    Feng, Youji
    Wang, Changyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Socinski, M. A.
    Bondarenko, I. N.
    Karaseva, N. A.
    Makhson, A.
    Vynnychenko, I.
    Okamoto, I.
    Hon, J. K.
    Hirsh, V.
    Bhar, P.
    Berk, G. I.
    Iglesias, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345